Elective PCI ischemic preconditioning: Clinical gains durable up to six years

Low-tech myocardial protection: six-month event-free-survival gains from the procedure, reported in 2009, are mostly still evident years later in the randomized CRISP Stent study.

via The Heart

Xarelto Approved for ACS Secondary Prevention in Europe

The European Commission has approved a 2.5-mg twice-daily dosage based on the ATLAS ACS 2 TIMI 51 trial.

International Approvals

via Medscape news

Stroke costs to double by 2030: AHA statement

The statement calls for greater awareness of this "looming crisis" by policy makers at all levels of governance so that practical ways to avert it can be considered.

via The Heart

Rivaroxaban approved for ACS secondary prevention in Europe

The European Commission has approved a 2.5-mg twice-daily dosage based on the ATLAS ACS 2 TIMI 51 trial.

via The Heart

Risk of Diabetes With Statins

While one study is reassuring for older patients treated with statins, with researchers finding no evidence of an increased risk of diabetes in acute coronary syndrome patients, the other suggests that the more potent statins, such as rosuvastatin, atorvastatin, and simvastatin, do pose an increased risk compared with pravastatin.

Heartwire

via Medscape news

EnligHTN-1: BP drops durable, safe at one year, as renal-denervation mania grows

Twelve-month durability and safety results are exciting with this device, one investigator says. This year's EuroPCR program is jam-packed with new data and how-to sessions and included at least one live case where things did not go entirely according to plan.

via The Heart

Bioresorbable Drug-Eluting Scaffolds Emerging As The Dominant Device Of The Future For Percutaneous Coronary Interventions

The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial reported at EuroPCR 2013. DESolve (Elixir Medical Corporation) is the first bioresorbable PLLA-based polymer scaffold that releases novolimus, a major metabolite of sirolimus...

via Medical News Today

Superiority Of Bivalirudin Over Heparin Questioned

Results from a large observational study reported at EuroPCR 2013 question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI)...

via Medical News Today